PubMed Health⌕ Search

Biomedical subjects

L Rydgren

Publications and source records attributed to L Rydgren.

27 records · Page 2Linked to original sources
PubMed1976

Lymphocyte locomotion. I. The initiation, velocity, pattern, and path of locomotion in vitro.

The locomotive behaviour of human lymphocytes in coverslip preparations of clotted autoplasma was studied at +37 degrees C. Lymphocytes isolated from peripheral blood or from the tonsils did not move prior to membrane activation by means of incubation with phytohemagglutinin (PHA). After PHA stimulation the locomotion of 19 lymphocytes was analysed by time-lapse fliming. The locomotion was random, as evidenced by a median locomotive index of 0.64 (Q1-Q3 0.04-0.75) and comparatively slow, median velocity 15 mum/min (Q1-Q3 12-18). The locomotion of 5 other lymphocytes was studied at high magnification. It is suggested that the characteristic polarity of wandering lymphocytes, indicating the direction of movement, can be utilized in the analysis of the lymphocyte traffic in tissue sections of post-capillary high-endothelium venules.

Cell Movement↗
PubMed1976

Lymphocyte locomotion. II. The lymphocyte traffic over the post-capillary venules analysed by phase contrast microscopy of thin sections of rat lymph nodes.

Thin sections of lymph nodes from 14 rats were examined by phase contrast microscopy as regards direction of lymphoctes with amoeboid movement configuration (AMC) relative to the basement membrane of post-capillary high-endothelium venules (HE-cenules). Out of 118 lymphocytes with AMC, 82 appeared to be on theyr way into the venule from the lymph node parenchyma. This observation suggests that the lymphocyte traffic over the HE-venules is bi-directional, with the main migratory stream of lymphocytes from the lymph node parenchyma into the post-capillary venules.

Animals↗
PubMedDate not supplied

Initiation and direction of polymorphonuclear leucocyte locomotion. The particle collision hypothesis.

A simple model of the initiation of locomotion, the random movement and the directional locomotion during chemotaxis is derived from observations on moving human polymorphonuclear leucocytes (PMNs). This model provides a unifying concept of initiation of PMN locomotion, PMN random movement and PMN chemotaxis. The lamellipodium is thought to be the direction-determining cell organelle.

Cell Movement↗
PubMedDate not supplied

Random locomotion and phagocytosis of monocytes in undiluted normal serum and in undiluted SLE serum.

Time-lapse filming was performed with normal monocytes in normal serum and in SLE serum, with and without yeast cell phagocytosis. Undiluted sera were used. After incubation of the monocytes with SLE serum we found a decreased velocity of random movement and a change of morphology to more condensed, rounded-up and un-spread cells with a decreased yeast cell phagocytosis. No obvious correlation was found between the SLE serum induced impairment of monocyte function and disease activity, complement levels or the presence of immune complexes. We conclude that monocyte in vitro membrane functions, such as random motility, spreading and yeast cell phagocytosis, are impaired in the presence of undiluted SLE serum.

Adult↗
PubMedDate not supplied

D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study.

OBJECTIVE: To evaluate the usefulness of early treatment with D-Penicillamine (DPA) in rheumatoid arthritis. METHODS: The patients were recruited from a Swedish early RA cohort comprising 180 patients. All patients experiencing active and/or erosive disease 2 years from onset were asked to participate in a 2-year placebo-controlled DPA trial. Previous treatment with slow-acting anti-rheumatic drugs (SAARDs) or oral corticosteroids was not allowed. The main outcome variable was radiographic progression in the hands and feet evaluated according to Larsen. Clinical assessment including the Ritchie index, active joint count, and the HAQ-disability index was performed every 6th month. Patients were included in the analyses of efficacy until the endpoint of therapy. RESULTS: 111/180 patients were eligible for treatment, and 74 agreed to participate in the trial. 21/33 patients on DPA and 22/41 on placebo completed the study. More patients taking placebo stopped due to lack of response (p < 0.01). 27% of the patients on DPA were withdrawn due to side effects. Radiographic deterioration increased but most clinical variables improved in both trial arms. A large inter-individual variation was observed. The only significant difference in trend over 2 years between DPA and placebo was found for joint tenderness. However, the median trends for most clinical variables showed a more positive effect for DPA. The 37 patients who refused to participate in the trial in general fared somewhat worse than patients taking DPA and somewhat better than patients taking placebo. The remission rate was about the same in all 3 groups (12-13.5%). CONCLUSIONS: About two-thirds of all early definite RA patients were eligible for treatment using current criteria. Psychological readiness for early therapy was fairly modest with a high refusal rate. The difference in efficacy between DPA and placebo was small, but was in favour of DPA for most clinical variables. However, only joint tenderness showed a significantly better trend. No significant slowing of radiographic progression by DPA was found.

Antirheumatic Agents↗